Spartan CYP2C19 Test

CYP2C19 is a liver enzyme that metabolizes 15% of all prescribed drugs, including anti-platelet drugs, antidepressants, and PPIs. Carrying a CYP2C19 mutation can impair drug metabolism. In fact, 30% of Caucasians and 50% of Asians and Indians carry CYP2C19 mutations that impair drug metabolism. The Spartan CYP2C19 test is rapid, portable and allows real-time determination of a patient’s genotype. This aids in determining the appropriate antiplatelet treatment for said patient, leading to better patient outcomes, lower readmission rates, and lower-cost healthcare for everyone.